A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
This study is testing new, targeted medications for people with specific lung cancer mutations that have stopped responding to standard treatments. By focusing on these specific genetic changes, researchers hope to find more effective ways to stop the cancer from growing.
You may be eligible if you are at least 18 years old and have advanced or incurable lung cancer with specific genetic mutations like KRAS G12C. You must have already tried standard treatments and be healthy enough to perform daily activities.
Participants will receive experimental medications, sometimes combined with standard chemotherapy or immunotherapy, to see how well they work and ensure they are safe. You will be closely monitored by a medical team to track your health and how the cancer responds to the treatment.
This study is currently recruiting patients at specific medical centers in Arizona and California. It is a multi-phase study designed to carefully test these new drug combinations.
- 1Focuses on patients with specific lung cancer gene mutations.
- 2Tests new, targeted drugs designed to block cancer growth signals.
- 3Requires participants to have already completed standard cancer treatments.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.